Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - -

GlobeNewswireMar 26 21:15

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV

BenzingaMar 21 21:05

Virios Therapeutics: A Hold Rating With a New Price Target Amidst Clinical and Financial Challenges

TipRanksMar 6 19:38

Virios Therapeutics Reports Q4 Results

Seeking AlphaMar 1 23:49

Virios Therapeutics Q4 2023 GAAP EPS $(0.06) Beats $(0.09) Estimate

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent.

BenzingaFeb 29 22:17

Virios Therapeutics: Discussions Ongoing With Potential Partners to Fund Advancement of IMC-1 Into Phase 3 Development for FM >VIRI

Virios Therapeutics: Discussions Ongoing With Potential Partners to Fund Advancement of IMC-1 Into Phase 3 Development for FM >VIRI

Dow JonesFeb 29 22:16